170 related articles for article (PubMed ID: 19672256)
1. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Lomholt AF; Høyer-Hansen G; Nielsen HJ; Christensen IJ
Br J Cancer; 2009 Sep; 101(6):992-7. PubMed ID: 19672256
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
3. The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
Rolff HC; Christensen IJ; Svendsen LB; Wilhelmsen M; Lund IK; Thurison T; Høyer-Hansen G; Illemann M; Nielsen HJ;
J Surg Oncol; 2019 Dec; 120(8):1404-1411. PubMed ID: 31646652
[TBL] [Abstract][Full Text] [Related]
4. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
[TBL] [Abstract][Full Text] [Related]
5. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Tarpgaard LS; Christensen IJ; Høyer-Hansen G; Lund IK; Guren TK; Glimelius B; Sorbye H; Tveit KM; Nielsen HJ; Moreira JM; Pfeiffer P; Brünner N
Int J Cancer; 2015 Nov; 137(10):2470-7. PubMed ID: 25664394
[TBL] [Abstract][Full Text] [Related]
6. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
Thurison T; Lomholt AF; Rasch MG; Lund IK; Nielsen HJ; Christensen IJ; Høyer-Hansen G
Clin Chem; 2010 Oct; 56(10):1636-40. PubMed ID: 20802096
[TBL] [Abstract][Full Text] [Related]
7. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
8. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Role of Circulating Soluble uPAR in Various Cancers: a Systematic Review and Meta-Analysis.
Liu KL; Fan JH; Wu J
Clin Lab; 2017 May; 63(5):871-880. PubMed ID: 28627814
[TBL] [Abstract][Full Text] [Related]
10. A Preliminary Study of the Value of Plasma microRNA-193b and Soluble Urokinase-Type Plasminogen Activator Receptor in Identifying Patients with Early-Stage Colorectal Cancer and.
Liu KL; Luo JL; Wu J; Wang YD; Fan HJ
Clin Lab; 2017 Nov; 63(11):1949-1953. PubMed ID: 29226653
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer.
Illemann M; Laerum OD; Hasselby JP; Thurison T; Høyer-Hansen G; Nielsen HJ; ; Christensen IJ
Cancer Med; 2014 Aug; 3(4):855-64. PubMed ID: 24889870
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
13. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
[TBL] [Abstract][Full Text] [Related]
16. Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
Jensen MK; Riisbro R; de Nully Brown P; Brünner N; Hasselbalch HC
Eur J Haematol; 2002 Jul; 69(1):43-9. PubMed ID: 12270061
[TBL] [Abstract][Full Text] [Related]
17. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
18. Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: biological variation, reference intervals and clinical useful cut-points.
Thurison T; Christensen IJ; Lund IK; Nielsen HJ; Høyer-Hansen G
Clin Chim Acta; 2015 Jan; 439():84-90. PubMed ID: 25305537
[TBL] [Abstract][Full Text] [Related]
19. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA.
Høgdall CK; Christensen IJ; Stephens RW; Sørensen S; Nørgaard-Pedersen B; Nielsen HJ
APMIS; 2002 Sep; 110(9):630-8. PubMed ID: 12529016
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
Almasi CE; Brasso K; Iversen P; Pappot H; Høyer-Hansen G; Danø K; Christensen IJ
Prostate; 2011 Jun; 71(8):899-907. PubMed ID: 21456072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]